Abstract
Purpose: :
The aim of this study was to determine the influence of 0,1% diclofenac sodium ophthalmic solution as adjunctive therapy with loteprednol on postoperative intensity of inflammation in the anterior chamber and on foveal and perifoveal retinal thickness.
Methods: :
36 eyes of 36 patients aged 47 to 87 years qualified for phacoemulsification with IOL implantation were enrolled for prospective randomized study. Patients were divided into 2 groups: group I (D+L)- 0.1% diclofenac with 0.5% loteprednol etabonate and group II (L) - monotherapy with 0.5% loteprednol etabonate. BCVA, intraocular pressure, laser flare-cell photometry in anterior chamber inflammation and foveal and perifoveal thickness were measured before surgery and on Day 1 and 1, 2, 6 weeks after surgery.
Results: :
No statistically significant differences in BCVA and intraocular pressure were observed. Analysis of group treated with 0.1% Dicloabak with ophthalmic steroid 7 and 14 days after surgery showed faster decrease of laser flare-cell photometry values comparing to group II. Statistically significant increase in perifoveal and foveal thickness in OCT was observed in group II 2 and 6 weeks after the surgery. In group I decrease in perifoveal and foveal thickness was observed in comparison to preoperative values.
Conclusions: :
0,1% diclofenac sodium opthalmic solution used with loteprednol signifficantly decreases inflammatory response after phacoemusification.
Keywords: cataract • inflammation • treatment outcomes of cataract surgery